Humacyte Inc (NASDAQ: HUMA) on Friday, soared 4.40% from the previous trading day, before settling in for the closing price of $3.18. Within the past 52 weeks, HUMA’s price has moved between $2.75 and $9.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -21.76%. With a float of $104.39 million, this company’s outstanding shares have now reached $119.84 million.
Considering the fact that the conglomerate employs 183 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 35.2%, operating margin of -1042.56%, and the pretax margin is -1416.75%.
Humacyte Inc (HUMA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Humacyte Inc is 18.87%, while institutional ownership is 33.28%. The most recent insider transaction that took place on Dec 04 ’24, was worth 20,181. In this transaction Director of this company bought 4,600 shares at a rate of $4.39, taking the stock ownership to the 16,950 shares. Before that another transaction happened on Nov 19 ’24, when Company’s President, CEO and Director bought 1,797 for $4.44, making the entire transaction worth $7,979. This insider now owns 243,851 shares in total.
Humacyte Inc (HUMA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -21.76% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Humacyte Inc (HUMA) is currently performing well based on its current performance indicators. A quick ratio of 1.10 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
Compared to the last year’s volume of 2.23 million, its volume of 1.94 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 89.71%. Additionally, its Average True Range was 0.28.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 14.18%, which indicates a significant decrease from 95.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.72% in the past 14 days, which was lower than the 92.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.83, while its 200-day Moving Average is $5.31. Nevertheless, the first resistance level for the watch stands at $3.40 in the near term. At $3.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.62. If the price goes on to break the first support level at $3.18, it is likely to go to the next support level at $3.05. Should the price break the second support level, the third support level stands at $2.96.
Humacyte Inc (NASDAQ: HUMA) Key Stats
Market capitalization of the company is 427.18 million based on 125,859K outstanding shares. Right now, sales total 0 K and income totals -110,780 K. The company made 0 K in profit during its latest quarter, and -39,200 K in sales during its previous quarter.
